Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 3/20 | 0.38 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.37 |
| ▸ | PDK3 | Q15120 | 3/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 3/20 | 0.37 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.37 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25315122 | 0.85 | BMPR1B (0.49) | CYP2D6CYP2C9SMN1; SMN2BMPR1BBMPR1A | |
| SCHEMBL31178338 | 0.85 | BMPR1B (0.49) | CYP2D6CYP2C9SMN1; SMN2BMPR1BBMPR1A | |
| SCHEMBL5541492 | 0.82 | SRD5A1 (0.47) | CYP2D6CYP2C9SMN1; SMN2ATAD2BMPR1B | |
| SCHEMBL19910573 | 0.81 | SMN1; SMN2 (0.40) | CYP2D6CYP2C9SMN1; SMN2ATAD2PDK1 | |
| SCHEMBL1119387 | 0.81 | SRD5A1 (0.47) | CYP2D6CYP2C9SMN1; SMN2ATAD2BMPR1B | |
| SCHEMBL5541484 | 0.81 | SMN1; SMN2 (0.43) | CYP2D6CYP2C9SMN1; SMN2ATAD2BMPR1B | |
| SCHEMBL8126458 | 0.81 | ATAD2 (0.59) | CYP2D6CYP2C9SMN1; SMN2ATAD2PDK1 | |
| SCHEMBL29896920 | 0.81 | SRD5A1 (0.47) | CYP2D6CYP2C9SMN1; SMN2ATAD2BMPR1B | |
| SCHEMBL19910561 | 0.79 | TP53 (0.42) | CYP2D6CYP2C9SMN1; SMN2ATAD2BMPR1B | |
| SCHEMBL21886560 | 0.78 | TRIM24 (0.43) | CYP2D6CYP2C9SMN1; SMN2ATAD2BMPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-12-05 | — | — | US | disclosed |
| EP-4465982-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| US-11976067-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | CYP2D6 2182/4885CYP2C9 2804/4885SMN1; SMN2 235/4885 |
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | CYP2D6 2232/4885CYP2C9 2790/4885SMN1; SMN2 259/4885 |
| US-11976067-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, LDLR | CYP2D6 2182/4885CYP2C9 2804/4885SMN1; SMN2 235/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | CYP2D6 2232/4885CYP2C9 2790/4885SMN1; SMN2 259/4885 |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | CYP2D6 2232/4885CYP2C9 2790/4885SMN1; SMN2 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.